<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Endoluminal therapy is an option for selected patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To assess long-term outcomes of patients treated with endoluminal therapy with the goal of complete eradication of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: Retrospective cohort study </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS: Selected patients referred with dysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>INTERVENTION: Endoluminal therapy combining resection and photodynamic therapy, radiofrequency ablation, and/or <z:chebi fb="17" ids="49474,49475">argon</z:chebi> plasma coagulation treatment was individualized based on patient and lesion characteristics, technique evolution, and interval response </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASUREMENTS: We assessed complete eradication of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath>, and recurrences </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: A total of 166 patients were treated and had at least 1 year of follow-up </plain></SENT>
<SENT sid="7" pm="."><plain>Complete elimination of <z:hpo ids='HP_0002664'>neoplasia</z:hpo> was achieved in 157 patients (95%) and complete elimination of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> in 137 patients (83%) </plain></SENT>
<SENT sid="8" pm="."><plain>After therapy, patients were followed for 33 (range 18-58) months </plain></SENT>
<SENT sid="9" pm="."><plain>Among patients who achieved complete elimination of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath>, subsequent recurrent <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> was detected in 48 (35%) and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in 12 (9%) </plain></SENT>
<SENT sid="10" pm="."><plain>Among those who achieved only complete elimination of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, recurrent <z:mpath ids='MPATH_589'>dysplasia</z:mpath> was detected in 6 of 19 patients (32%) </plain></SENT>
<SENT sid="11" pm="."><plain>Multifocal <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and patient's age were <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and/or <z:mp ids='MP_0002038'>carcinoma</z:mp> recurrence risk factors in the multivariable and univariable analyses </plain></SENT>
<SENT sid="12" pm="."><plain>Complete elimination of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> was a protective factor in the univariable analysis </plain></SENT>
<SENT sid="13" pm="."><plain>Retreatment achieved remission in 90% of cases </plain></SENT>
<SENT sid="14" pm="."><plain>Forty-two patients (23.9%) had complications, including 21 with stricture (11.9%) and 1 treatment-related <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>LIMITATIONS: Retrospective study and evolution of endoscopic modalities </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSION: Multiple-mode endoluminal therapy for <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or early <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> with intention to complete eradication of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> was successful, with low observed recurrence of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="17" pm="."><plain>However, recurrence of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> occurs in one-third of cases and supports continued endoscopic surveillance even after complete eradication </plain></SENT>
</text></document>